Current report
Open the filing on sec.gov
Neumora Therapeutics, Inc. (NMRA)
Nasdaq: NMRA · Biological Products, (No Diagnostic Substances) · Watertown, MA · filing with the SEC since 2021
The companyfiscal 2025, as filed
Revenuen/a
Net income-$237M+2.8%
Earnings per share$-1.45+5.2%
Operating cash flow-$206M-12.8%
Cash$183M+28.4%
Debt$54.5M
Shareholders’ equity$104M-63.8%
Shares, diluted163.4M+2.5%
Return on equity-228.1%
The recordfrom its filings
Filings in 202650
Newest filingOct 30 · 8-K
Annual reportMar 30, 2026
Quarterly reportAug 14, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$1.1M
Insider buys, 12 months$5.0M
Patents granted19
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Jun 2026Net income -$213MCash from operations -$181Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Notice of intended sale
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Notice of intended sale
Open the filing on sec.gov
Notice of intended sale
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.